Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical Device Regulations In Latin America And The Way Forward

Executive Summary

Akhila Krishnan reviews the different regulatory requirements for medical devices in five Latin American countries and discusses how harmonization initiatives will make things easier for manufacturers in this guest column.

You may also be interested in...



Can A Transformed ANVISA Sustain Torrent's Brazilian Mojo?

Price gains and a regulator that has turned more responsive appear to be among the key factors contributing to the improving sentiment in Brazil for India's Torrent even as the South American nation tackles intense political and economic turbulence. While Torrent reported a sharp decline in its earnings in the first quarter largely due to exceptional gains in the comparable previous period, its Brazilian business is looking up.

Medtech Reform Breakthrough As EU Reaches Agreement on Future Regulations

Nearly eight years after it kicked off initial negotiations, the EU has finally agreed on how medical devices and IVDs will be regulated for the foreseeable future1.

US FDA's Expedited Access Pathway: 17 Medical Devices And Counting

Some 17 medical devices have been granted designation under the US Food and Drug Administration's year-old expedited access pathway (EAP) for helping to fast track innovative devices to market1.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT103586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel